Why cash burn is the most important variable
Chapter 1 of 14 · 6 min
Understand why this course is marked 'Critical' and why 90% of small-cap investors lose money here
10x Insight
Share issues are the single most common reason small cap investors lose money on the Stockholm stock exchange.
The silent killer — share issues kill more investors than bankruptcy
When new investors hear the word 'risk' they think of bankruptcy — the company going under, the stock falling to zero, the capital disappearing overnight. It is a dramatic, visible, and (relatively) rare event. The real killer is quieter, slower, and more insidious: share issues. Every year Swedish small caps issue hundreds of billions of kronor in new share issues. Some are legitimate — the company grows quickly and needs capital to finance growth. But many are life-sustaining: the company burns money faster than it earns it, and instead of solving the underlying problem (the business model) management sends out a new share issue every year. The result is 'death by a thousand dilutions'. The stock may not fall to zero — it is just diluted so much that your original holding becomes worthless. The Sinch stock fell from 600 SEK to 30 SEK between 2021 and 2024 — 95% value destruction. That did not happen through a single catastrophe but through a combination of high burn rate, massive share issues, debt build-up, and dilution. This is the pattern V19 is designed to catch.
⚠️ WARNING
Share issues are the single most common reason small cap investors lose money on the Stockholm stock exchange. Statistics from the Financial Supervisory Authority show that dilution through share issues costs Swedish retail investors more than all bankruptcies combined.
Cash is the blood — the company's oxygen system
Think of a company as a living organism. The product is the brain, the customers are the muscles, the management is the nervous system — but cash is the blood. Without blood the organism dies no matter how well the brain works. The cash flow from operations (operating cash flow) is the heart pumping new blood. If the heart does not pump enough, the organism must get blood transfusions (share issues) to survive. This is fundamental: a company with a fantastic product, strong customers, and visionary management can still die if the cash runs out.
NIBE has issued billions over the years but every share issue has financed new growth that more than compensates for the dilution. Bong (Bong Lerenius) issued repeatedly to cover ongoing losses — the dilution destroyed investors completely. The difference between these two companies is not the product or the market — it is HOW the share issue is used. Growth issue = investment; survival issue = subsidising a non-functioning business model. V19 teaches you to distinguish these.
💡 INSIGHT
A company can have the best product, the largest market, and the smartest CEO — and still go under if the cash runs out. Cash is the blood; share issues are blood transfusions. The heart (operating cash flow) must beat on its own before the company is healthy.
Why V19 is the Risk category — and sits last in AKM1
AKM1 has 19 variables divided into 7 categories: Valuation, Growth, Profitability, Stability, Moat, Catalyst, and Risk. Risk is the last category and V19 is the only variable in the category. This is no coincidence — it is design. All the previous 18 variables describe opportunities: how fast the company grows, how good the margins are, how strong the moat is. V19 describes survival. It does not matter how good the first 18 variables look if the company goes into bankruptcy or dilutes you to zero. V19 is 'the big knockout question' — it has the power to invalidate all positive signals. A company with V1=5 (fantastic growth), V6=5 (EBITDA 30%), V10=5 (strong moat) can still be a lousy investment if V19=1 (runway under 6 months, acute share issue risk). That is why V19 sits last: you assess all other variables first, and if V19 is bad — you move on. Without the V19 check, all other analyses are meaningless.
Three categories of share issue risk — a taxonomy
To systematise the V19 analysis it is useful to distinguish three categories of share issue risk. CATEGORY 1 — Acute share issue risk (V19 score 1): runway under 6 months, the company MUST issue within 3-4 months to avoid bankruptcy. Sinch in late 2020 belonged here. Investing in this situation is high risk; the company can be saved by a share issue but the dilution becomes massive. CATEGORY 2 — High share issue risk (V19 score 2): runway 6-12 months, the company needs to issue within 6-9 months. The price of the share issue becomes decisive — a sound issue (80%+ of market) can be managed; a desperate issue (below 70%) destroys value. CATEGORY 3 — Needs-to-plan risk (V19 score 3): runway 12-24 months, the company has time to consider alternatives — loans, asset sales, cost reductions, or an early issue at a good price. This is the 'grey zone' where sophisticated management can avoid a share issue through strategic moves. This taxonomy helps prioritise the analysis: category 1 requires immediate decision-making (sell or subscribe); category 3 allows patient monitoring. Positive categories (score 4-5) are 'self-funding' and 'strongly self-funding' — share issue risk is minimal.
📖 DEFINITION
Share issue risk taxonomy: C1 (acute, runway <6 months, MUST issue within 3-4 months), C2 (high, 6-12 months, needs to issue within 6-9 months), C3 (needs to plan, 12-24 months, has time to consider alternatives). C4-5: self-funding.
⚡ KEY INSIGHTS Share issues are the silent killer — more common than bankruptcy as a cause of investor losses Cash is the company's blood; share issues are blood transfusions; operating cash flow is the heart V19 sits last in AKM1 as 'the big knockout question' — it can invalidate all positive signals Growth issue (investment) ≠ survival issue (subsidising a non-functioning business model) Three categories of share issue risk: C1 (acute <6 months), C2 (high 6-12 months), C3 (planning, -12-24 months) 2